Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-HCVAD vs R-CHOP in Aggressive B-Cell Non-Hodgkin's Lymphoma
NCT00290498Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2005
- Primary completion
- Aug 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rituximab in B-cell non-Hodgkin lymphoma (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Response Rate R-HCVAD vs. R-CHOP at 3 years. Started Aug 2005; status: completed.
02
Drugs
rituximab
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT00290498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290498.